Integrative Research Laboratories Sweden Ab

Nsab, Filial Af Neurosearch Sweden Ab, Sverige

A. Carlsson Research Ab

Teva Pharmaceuticals International Gmbh

Ivax International Gmbh

Integrative Research Laboratories

Integrated Research Laboratories Sweden Ab

Nsab, Filial Af Neurosearch Ab, Sverige

Neurosearch Sweden Ab

Nsab, Filial Af Neurosearch Sweden Ab

Irl 790 Ab

Clas Sonesson

Nicholas Ross Waters

Lars Swanson

Fredrik Pettersson

Susanna Waters

Joakim Tedroff

Peder Svensson

Jonas B Karlsson

Inese Reine

Ingela Marianne Svan

Bengt Andersson

Maija Buksa

Brian Frøstrup

Anne Zimmermann

Jenny Maria Carlberg, Legal Representative

Thomas Pittelkow

Anders Kristoffer Lilja

Liselott Lilja Rönnqvist

Mikael Andersson

Jenny Maria Carlberg

Nicholas Waters

Ross Nicholas Waters

Joakim Mihkel Tedroff

Ingela Marianne Svan, Legal Representative

Anders Kristoffer Lilja, Legal Representative

Liselott Lilja Rönnqvist, Legal Representative

There is disclosed a salt of Formula III, a method for manufacturing thereof as well as uses thereof. (Formula III), wherein X is H or OH, Y is H or a cation selected from the group consisting of Li, Na and K, is a single bond or a double bond, and n is 0.5 or 1.

Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

(+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

The disclosure provides a process for manufacturing thereof a salt of Formula IIb: 

The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R, R, R, Rand Rrepresents H or F, Rrepresents H or CHRrepresents H or C-Calkyl, wherein at least two of R, R, R, Rand Rrepresent F, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

The present disclosure relates to certain novel compounds and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.

Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission

The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; Ris OSOCF, OSOCH, SOR, SOR, COR, NO, or CONHRand when X is CH or C Rmay also be CF, CN, F, Cl, Br, or I; Ris a C-Calkyl, an allyl, CHSCH, CHCHOCH, CHCHCHF, CHCF, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or &#x2014;(CH)&#x2014;R; Ris a C-Calkyl CF, or N(R); Ris a C-Ccycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed

Modulators of dopamine neurotransmission

The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission

The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.

3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydrochloride salt, a process for the preparation of this polymorphic form, pharmaceutical compositions comprising polymorphic Form II, and methods of uses of this polymorphic form.

Polymorphic form of pridopidine hydrochloride

3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications. 

3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted phenylpiperidines of the formula 1: wherein R is as defined herein.

3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission

Growing community of inventors

Billdal, Sweden

Clas Sonesson